Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MALIN L HULTCRANTZ

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1578921664
CMS profile
5405832
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$4,540.45

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,400.00 1
Food and Beverage $140.45 2

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $4,400.00 1
Janssen Scientific Affairs, LLC $79.32 1
Janssen Biotech, Inc. $61.13 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MALIN L HULTCRANTZ

NPI 1578921664 · CMS profile ID 5405832

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578921664?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MALIN L HULTCRANTZ, NPI 1578921664, CMS profile ID 5405832. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578921664?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MALIN L HULTCRANTZ, NPI 1578921664, CMS profile ID 5405832. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578921664?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MALIN L HULTCRANTZ, NPI 1578921664, CMS profile ID 5405832, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1578921664?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $4,540.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Scientific Affairs, LLC $79.3212/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887241069 CMS
Janssen Biotech, Inc. $61.1312/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886282265 CMS
GlaxoSmithKline, LLC. $4,400.0010/20/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944659733 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $451.18 7
PY2021 $1,830.00 2
PY2022 $4,540.45 3
PY2023 $3,579.51 4
PY2024 $9,375.22 7
PY2025 $8,299.71 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,507,253.15 50
PY2024 Principal investigator $621,082.28 99
PY2023 Recipient $50.00 1
PY2023 Principal investigator $320,573.02 53
PY2022 Principal investigator $98,174.79 7
PY2021 Principal investigator $56,106.62 10
PY2020 Principal investigator $64,226.75 8
PY2019 Recipient $840.72 11
PY2019 Principal investigator $100,589.30 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

99 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $11,142.68 12/13/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CEN
BELANTAMAB MAFODOTIN IN COMBINATION WITH NIROGACESTAT IN PATIENTS WITH No dispute reported 06/30/2026 1127551300
Principal investigator 1 ABBVIE INC. $4,329.04 12/05/2024 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1100760109
Principal investigator 1 BeiGene USA, Inc. $12,933.00 11/26/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119725733
Principal investigator 1 ABBVIE INC. $7,648.77 11/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
A Dose Escalation and Expansion Study of ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1100754181
Principal investigator 1 BeiGene USA, Inc. $8,967.00 10/29/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119725731
Principal investigator 1 GlaxoSmithKline, LLC. $10,740.64 10/17/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127551292
Principal investigator 1 BeiGene, Ltd. $58,953.24 10/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CTR
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718745
Principal investigator 1 ABBVIE INC. $15,270.94 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1100746912
Principal investigator 1 BeiGene USA, Inc. $12,141.00 09/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119725729
Principal investigator 1 BeiGene USA, Inc. $53,958.00 09/10/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119725727
Principal investigator 1 ABBVIE INC. $26,073.50 09/04/2024 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1100740798
Principal investigator 1 GlaxoSmithKline, LLC. $1,901.50 09/04/2024 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CENTER
CHARACTERIZATION OF CORNEAL EPITHELIAL CHANGES IN PARTICIPANTS TREATED No dispute reported 06/30/2026 1127521387
Principal investigator 1 GlaxoSmithKline, LLC. $46,068.00 08/13/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CEN
Not supplied No dispute reported 06/30/2026 1127522650
Principal investigator 1 ABBVIE INC. $4,194.04 08/02/2024 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1100734194
Principal investigator 1 GlaxoSmithKline, LLC. $14,090.09 07/18/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127551286
Principal investigator 1 ABBVIE INC. $5,183.47 07/05/2024 Non-covered Recipient Entity
MEMORIAL SLOAN-KETTERING CANCER CTR
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1100727346
Principal investigator 1 GlaxoSmithKline, LLC. $1,688.69 06/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
CHARACTERIZATION OF CORNEAL EPITHELIAL CHANGES IN PARTICIPANTS TREATED No dispute reported 06/30/2026 1127521385
Principal investigator 1 ABBVIE INC. $9,330.27 06/06/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1100722678
Principal investigator 1 BeiGene, Ltd. $1,254.00 05/17/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119714177
Principal investigator 1 BeiGene, Ltd. $1,254.00 05/17/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119714207
Principal investigator 1 BeiGene, Ltd. $3,829.00 05/17/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119714279
Principal investigator 1 BeiGene, Ltd. $1,254.00 05/17/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119714301
Principal investigator 1 BeiGene, Ltd. $1,254.00 05/17/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119723425
Principal investigator 1 BeiGene, Ltd. $3,829.00 05/17/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119723495
Principal investigator 1 BeiGene, Ltd. $1,254.00 05/17/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119723593
Principal investigator 1 BeiGene, Ltd. $3,829.00 05/17/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119730617
Principal investigator 1 ABBVIE INC. $7,073.47 05/09/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1100717490
Principal investigator 1 BeiGene, Ltd. $1,254.00 04/26/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119714143
Principal investigator 1 BeiGene, Ltd. $3,829.00 04/26/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119714181
Principal investigator 1 BeiGene, Ltd. $1,254.00 04/26/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119714183
Principal investigator 1 BeiGene, Ltd. $1,254.00 04/26/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119714319
Principal investigator 1 BeiGene, Ltd. $1,254.00 04/26/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119714325
Principal investigator 1 BeiGene, Ltd. $1,254.00 04/26/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119714327
Principal investigator 1 BeiGene, Ltd. $3,829.00 04/26/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119723509
Principal investigator 1 BeiGene, Ltd. $3,829.00 04/26/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119723539
Principal investigator 1 BeiGene, Ltd. $1,254.00 04/26/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119723573
Principal investigator 1 BeiGene, Ltd. $3,829.00 04/26/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119730605
Principal investigator 1 GlaxoSmithKline, LLC. $9,203.61 04/24/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127521395
Principal investigator 1 GlaxoSmithKline, LLC. $3,378.00 04/11/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE I/II, OPEN-LABEL, PARALLEL-GROUP, DOSE ESCALATION AND EXPANSIO No dispute reported 06/30/2026 1127546069
Principal investigator 1 ABBVIE INC. $14,962.05 04/04/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1100711702
Principal investigator 1 GlaxoSmithKline, LLC. $10,551.29 03/19/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE I/II, OPEN-LABEL, PARALLEL-GROUP, DOSE ESCALATION AND EXPANSIO No dispute reported 06/30/2026 1127521391
Principal investigator 1 GlaxoSmithKline, LLC. $22,774.93 03/19/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE I/II, OPEN-LABEL, PARALLEL-GROUP, DOSE ESCALATION AND EXPANSIO No dispute reported 06/30/2026 1127551298
Principal investigator 1 BeiGene, Ltd. $1,254.00 03/18/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718047
Principal investigator 1 BeiGene, Ltd. $3,829.00 03/18/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718049
Principal investigator 1 BeiGene, Ltd. $1,254.00 03/18/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718051
Principal investigator 1 BeiGene, Ltd. $1,254.00 03/18/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718053
Principal investigator 1 BeiGene, Ltd. $1,254.00 03/18/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718055
Principal investigator 1 BeiGene, Ltd. $3,829.00 03/18/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718057
Principal investigator 1 BeiGene, Ltd. $1,254.00 03/18/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718059
Principal investigator 1 BeiGene, Ltd. $3,829.00 03/18/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718061
Principal investigator 1 BeiGene, Ltd. $3,829.00 03/18/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718063
Principal investigator 1 BeiGene, Ltd. $1,254.00 03/18/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119727005
Principal investigator 1 BeiGene, Ltd. $1,254.00 03/18/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119727007
Principal investigator 1 BeiGene, Ltd. $3,829.00 03/18/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119727009
Principal investigator 1 BeiGene, Ltd. $1,254.00 03/18/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119727011
Principal investigator 1 GlaxoSmithKline, LLC. $2,227.80 03/12/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127551294
Principal investigator 1 ABBVIE INC. $20,314.28 03/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1100706310
Principal investigator 1 BeiGene, Ltd. $1,254.00 02/21/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119717775
Principal investigator 1 BeiGene, Ltd. $3,829.00 02/21/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119717779
Principal investigator 1 BeiGene, Ltd. $1,254.00 02/21/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119717783
Principal investigator 1 BeiGene, Ltd. $1,254.00 02/21/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119717787
Principal investigator 1 BeiGene, Ltd. $3,829.00 02/21/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119717791
Principal investigator 1 BeiGene, Ltd. $3,829.00 02/21/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119717795
Principal investigator 1 GlaxoSmithKline, LLC. $6,916.44 02/08/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127521389
Principal investigator 1 GlaxoSmithKline, LLC. $893.70 02/08/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127521393
Principal investigator 1 GlaxoSmithKline, LLC. $43.20 02/08/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127546071
Principal investigator 1 GlaxoSmithKline, LLC. $842.40 02/08/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127546073
Principal investigator 1 GlaxoSmithKline, LLC. $205.13 02/08/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127546079
Principal investigator 1 GlaxoSmithKline, LLC. $810.00 02/08/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127546081
Principal investigator 1 GlaxoSmithKline, LLC. $4,108.18 02/08/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127551290
Principal investigator 1 GlaxoSmithKline, LLC. $206.52 02/08/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127551296
Principal investigator 1 GlaxoSmithKline, LLC. $6,302.62 02/07/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127551288
Principal investigator 1 ABBVIE INC. $17,698.24 02/02/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1100702928
Principal investigator 1 BeiGene, Ltd. $1,254.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718331
Principal investigator 1 BeiGene, Ltd. $1,254.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718333
Principal investigator 1 BeiGene, Ltd. $3,829.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718335
Principal investigator 1 BeiGene, Ltd. $1,254.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718337
Principal investigator 1 BeiGene, Ltd. $3,829.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718339
Principal investigator 1 BeiGene, Ltd. $1,254.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718341
Principal investigator 1 BeiGene, Ltd. $1,254.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718343
Principal investigator 1 BeiGene, Ltd. $3,829.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718345
Principal investigator 1 BeiGene, Ltd. $1,254.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718347
Principal investigator 1 BeiGene, Ltd. $1,254.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718349
Principal investigator 1 BeiGene, Ltd. $3,829.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119718351
Principal investigator 1 BeiGene, Ltd. $1,254.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119730227
Principal investigator 1 BeiGene, Ltd. $1,254.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119730229
Principal investigator 1 BeiGene, Ltd. $3,829.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119730231
Principal investigator 1 BeiGene, Ltd. $1,254.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119730233
Principal investigator 1 BeiGene, Ltd. $1,254.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119730235
Principal investigator 1 BeiGene, Ltd. $3,829.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119730237
Principal investigator 1 BeiGene, Ltd. $5,784.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119730239
Principal investigator 1 BeiGene, Ltd. $5,733.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119730241
Principal investigator 1 BeiGene, Ltd. $4,902.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119730243
Principal investigator 1 BeiGene, Ltd. $1,254.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119730959
Principal investigator 1 BeiGene, Ltd. $3,829.00 01/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) No dispute reported 06/30/2026 1119730961
Principal investigator 1 ABBVIE INC. $13,001.32 01/04/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed Refractory Multiple Myeloma No dispute reported 06/30/2026 1100698781
Principal investigator 1 GlaxoSmithKline, LLC. $24,769.08 01/04/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127546083
Principal investigator 1 GlaxoSmithKline, LLC. $4,097.91 01/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127546075
Principal investigator 1 GlaxoSmithKline, LLC. $2,795.24 01/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING AT MONMOUTH - RETAIL
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1127546077